In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Sabatelli, F.; Patel, R.; Mann, P. A.; Mendrick, C. A.; Norris, C. C.; Hare, R.; Loebenberg, D.; Black, T. A.; McNicholas, P. M.

doi:10.1128/aac.00163-06

Cited by 491Antifungal resistance and susceptibilityFungal Infections and StudiesFungal Plant Pathogen Control

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Open access

Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A. +1 more·2006·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.00163-06

Open this paper in CoChat — free account

Abstract

The in vitro activity of the novel triazole antifungal agent posaconazole (Noxafil; SCH 56592) was assessed in 45 laboratories against approximately 19,000 clinically important strains of yeasts and molds. The activity of posaconazole was compared with those of itraconazole, fluconazole, voriconazole, and amphotericin B against subsets of the isolates. Strains were tested utilizing Clinical and Laboratory Standards Institute broth microdilution methods using RPMI 1640 medium (except for amphotericin B, which was frequently tested in antibiotic medium 3). MICs were determined at the recommended endpoints and time intervals. Against all fungi in the database (22,850 MICs), the MIC(50) and MIC(90) values for posaconazole were 0.063 microg/ml and 1 mug/ml, respectively. MIC(90) values against all yeasts (18,351 MICs) and molds (4,499 MICs) were both 1 mug/ml. In comparative studies against subsets of the isolates, posaconazole was more active than, or within 1 dilution of, the comparator drugs itraconazole, fluconazole, voriconazole, and amphotericin B against approximately 7,000 isolates of Candida and Cryptococcus spp. Against all molds (1,702 MICs, including 1,423 MICs for Aspergillus isolates), posaconazole was more active than or equal to the comparator drugs in almost every category. Posaconazole was active against isolates of Candida and Aspergillus spp. that exhibit resistance to fluconazole, voriconazole, and amphotericin B and was much more active than the other triazoles against zygomycetes. Posaconazole exhibited potent antifungal activity against a wide variety of clinically important fungal pathogens and was frequently more active than other azoles and amphotericin B.

Integrity signals

Registry

Crossref · 10.1128/aac.00163-06

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Loss of SrbA resulted in a strain of A. fumigatus highly susceptible to fluconazole, an azole that normally has minimal activity against A. fumigatus.
“Interestingly, loss of SrbA resulted in a strain of A. fumigatus highly susceptible to fluconazole, an azole that normally has minimal activity against A. fumigatus [58],[59].”
From A Sterol-Regulatory Element Binding Protein Is Required for Cell Polarity, Hypoxia Adaptation, Azole Drug Resistance, and Virulence in Aspergillus fumigatus (2008) · cites this paper as [58]

National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736 · see citing works
Heart-Lung Transplantation
Yarbrough, W. M., Robbins, R. C., & Mallidi, H. R. (2016) · CRC Press eBooks · doi:10.3109/9781439802571-25 · Cited by 2,158 · see citing works
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Beck‐Sagué, C. M., Jarvis, W. R., & System, N. N. I. S. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140 · see citing works
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784 · see citing works
Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997
McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D., & Warnock, D. W. (2001) · Clinical Infectious Diseases · doi:10.1086/322606 · Cited by 657 · see citing works
Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 Cases
van Burik, J. H., Hare, R. S., Solomon, H. F., Corrado, M. L., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/500212 · Cited by 614 · see citing works
Posaconazole as Salvage Therapy for Zygomycosis
Greenberg, R. N., Mullane, K. M., van Burik, J. H., RAAD, I. I., Abzug, M. J., Anstead, G. M., Herbrecht, R., Langston, A. A., Marr, K. A., Schiller, G. J., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.126-133.2006 · Cited by 552 · see citing works
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky‐Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N. E., Kauffman, C. A., Cleary, J. D., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 494 · see citing works
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 477 · see citing works
Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1032-1037.2002 · Cited by 402 · see citing works
The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: results of population-based laboratory active surveillance.
Rees, J. R., Pinner, R. W., Hajjeh, R. A., Brandt, M. E., & Reingold, A. L. (1998) · Clinical Infectious Diseases · doi:10.1093/clinids/27.5.1138 · Cited by 397 · see citing works
In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes
Sun, Q. N., Fothergill, A. W., McCarthy, D. I., Rinaldi, M. G., & Graybill, J. R. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1581-1582.2002 · Cited by 365 · see citing works
The need for new antibiotics
Livermore, D. M. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1465-0691.2004.1004.x · Cited by 316 · see citing works
In vitro susceptibilities of zygomycetes to conventional and new antifungals
Dannaoui, É. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg020 · Cited by 313 · see citing works
Newer Systemic Antifungal Agents
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 308 · see citing works
Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions
RAAD, I. I., Hachem, R. Y., Herbrecht, R., Graybill, J. R., Hare, R. S., Corcoran, G., & Kontoyiannis, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/503425 · Cited by 299 · see citing works
Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14α-Sterol Demethylases from Aspergillus fumigatus and Candida albicans Provide Insights into Posaconazole Binding
Li, X., Madison, V., Chau, A. S., Loebenberg, D., Palermo, R. E., & McNicholas, P. M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.568-574.2004 · Cited by 266 · see citing works
In Vitro Activities of New and Conventional Antifungal Agents against ClinicalScedosporiumIsolates
Meletiadis, J., Meis, J. F. G. M., Mouton, J. W., Rodriquez-Tudela, J. L., Donnelly, J. P., Verweij, P. E., & the EUROFUNG Network (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.62-68.2002 · Cited by 232 · see citing works
Application of Real-Time Quantitative PCR to Molecular Analysis of Candida albicans Strains Exhibiting Reduced Susceptibility to Azoles
Chau, A. S., Mendrick, C. A., Sabatelli, F. J., Loebenberg, D., & McNicholas, P. M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2124-2131.2004 · Cited by 187 · see citing works
Self-citation
In Vitro Activities of Four Novel Triazoles against Scedosporium spp
Carrillo, A., & Guarro, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.2151-2153.2001 · Cited by 182 · see citing works
Posaconazole
Keating, G. M. (2005) · Drugs · doi:10.2165/00003495-200565110-00007 · Cited by 158 · see citing works
In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2862-2864.2001 · Cited by 143 · see citing works
A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)
Manavathu, E. K. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.229 · Cited by 140 · see citing works
In Vitro Susceptibilities of Candida dubliniensis Isolates Tested against the New Triazole and Echinocandin Antifungal Agents
Pfaller, M. A., Messer, S. A., Gee, S. F., Joly, S., Pujol, C., Sullivan, D. J., Coleman, D. C., & Soll, D. R. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.3.870-872.1999 · Cited by 137 · see citing works
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
Perfect, J. R., Cox, G. M., Dodge, R. K., & Schell, W. A. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.8.1910 · Cited by 128 · see citing works
In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole
Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E., & Hajjeh, R. A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3242 · Cited by 128 · see citing works
In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida
Cacciapuoti, A. F., Loebenberg, D., Corcoran, E., Menzel, F., Moss, E. L., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C. A., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2017-2022.2000 · Cited by 110 · see citing works
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp
Oakley, K. L., Moore, C. B., & Denning, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1124 · Cited by 101 · see citing works
Changes in susceptibility to posaconazole in clinical isolates of Candida albicans
Li, X. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh027 · Cited by 96 · see citing works
Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae
Pfaller, M. A., Messer, S. A., & Jones, R. N. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.233 · Cited by 92 · see citing works
In Vitro Activities of the New Antifungal Triazole SCH 56592 against Common and Emerging Yeast Pathogens
Barchiesi, F., Arzeni, D., Fothergill, A. W., Francesco, L. F. D., Caselli, F., Rinaldi, M. G., & Scalise, G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.226-229.2000 · Cited by 80 · see citing works
Posaconazole Is a Potent Inhibitor of Sterol 14α-Demethylation in Yeasts and Molds
MUNAYYER, H., Mann, P. A., Chau, A. S., Yarosh-Tomaine, T., Greene, J. R., Hare, R. S., Heimark, L. D., Palermo, R. E., Loebenberg, D., & McNicholas, P. M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3690-3696.2004 · Cited by 79 · see citing works
In Vitro and In Vivo Activities of Posaconazole against Coccidioides immitis
González, G. M., Tijerina, R., Najvar, L. K., Bocanegra, R. A., Rinaldi, M. G., Loebenberg, D., & Graybill, J. R. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1352-1356.2002 · Cited by 69 · see citing works
Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient
Herbrecht, R., Kessler, R., Kravanja, C., Meyer, M.-H., Waller, J., & Letscher‐Bru, V. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2003.09.033 · Cited by 64 · see citing works
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp
Law, D., Moore, C. B., & Denning, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2310 · Cited by 56 · see citing works
Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes
Gil‐Lamaignere, C., Hess, R., Salvenmoser, S., Heyn, K., Kappe, R., & Müller, F. C. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki140 · Cited by 26 · see citing works
Invasive mycoses: management and unmet medical needs
Patterson, T. F. (2001) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200112000-00001 · Cited by 14 · see citing works

Flagged first, then by citations

1 of the 38 references couldn’t be matched to a known paper.

Sorted by citations

Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J. A., Winston, D. J., Perfect, J. R., Ullmann, A. J., Walsh, T. J., HELFGOTT, D. C., Hołowiecki, J., Stockelberg, D., Goh, Y. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,802 · see citing works
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P. H., Langston, A. A., Tarantolo, S., Greinix, H., de Azevedo, W. M., Reddy, V. S., Boparai, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061098 · Cited by 1,339 · see citing works
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901 · see citing works
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 721 · see citing works
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Marty, F. M., Ostrosky‐Zeichner, L., Cornely, O. A., Mullane, K. M., Perfect, J. R., Thompson, G. R., Alangaden, G. J., Brown, J. W., Fredricks, D. N., Heinz, W., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00071-2 · Cited by 714 · see citing works
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619 · see citing works
An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients
LIMPER, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 608 · see citing works
ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others
Tortorano, A. M., Richardson, M. D., Roilides, E., van Diepeningen, A., Caira, M., Munoz, P., Johnson, E. M., Meletiadis, J., Pana, Z. D., Lackner, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12465 · Cited by 517 · see citing works
Molecular Phylogenetic Diversity, Multilocus Haplotype Nomenclature, and In Vitro Antifungal Resistance within the Fusarium solani Species Complex
O'Donnell, K. L., Sutton, D. A., Fothergill, A. W., McCarthy, D. I., Rinaldi, M. G., Brandt, M. E., Zhang, N., & Geiser, D. M. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02371-07 · Cited by 479 · see citing works
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 451 · see citing works
Antifungal Agents
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351 · see citing works
Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers
Krishna, G., Moton, A., Ma, L., Medlock, M. M., & McLeod, J. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01034-08 · Cited by 348 · see citing works
A Sterol-Regulatory Element Binding Protein Is Required for Cell Polarity, Hypoxia Adaptation, Azole Drug Resistance, and Virulence in Aspergillus fumigatus
Willger, S. D., Puttikamonkul, S., Kim, K.-H., Burritt, J. B., Grahl, N., Metzler, L. J., Barbuch, R., Bard, M., Lawrence, C. B., & Cramer, R. A. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000200 · Cited by 345 · see citing works
Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods
Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314 · see citing works
History of the development of antifungal azoles: A review on structures, SAR, and mechanism of action
Shafiei, M., Peyton, L., Hashemzadeh, M., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104240 · Cited by 295 · see citing works
In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents
Almyroudis, N. G., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., & Kusne, S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00452-07 · Cited by 284 · see citing works
Alternaria infections: laboratory diagnosis and relevant clinical features
Pastor, F., & Guarro, J. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02024.x · Cited by 241 · see citing works
Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy
Trifilio, S. M., Bennett, C. L., Yarnold, P. R., McKoy, J. M., Parada, J. P., Mehta, J., Chamilos, G., Palella, F. J., Kennedy, L. D., Mullane, K. M., et al. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705614 · Cited by 228 · see citing works
Posaconazole: A Broad-Spectrum Triazole Antifungal Agent
Nagappan, V., & Deresinski, S. C. (2007) · Clinical Infectious Diseases · doi:10.1086/523576 · Cited by 223 · see citing works
In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida , Aspergillus , Fusarium , and Scedosporium Species
Guinea, J., Peláez, T., Recio, S., Torres-Narbona, M., & Bouza, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01512-07 · Cited by 213 · see citing works
Antifungal Activity of Thymus vulgaris L. Essential Oil and Its Constituent Phytochemicals against Rhizopus oryzae: Interaction with Ergosterol
Mota, K. S. D. L., Pereira, F. D. O., de Oliveira, W. A., Lima, I. O., & Lima, E. D. O. (2012) · Molecules · doi:10.3390/molecules171214418 · Cited by 187 · see citing works
Treatment of zygomycosis: current and new options
Rogers, T. R. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm429 · Cited by 179 · see citing works
Invasive Fungal Infections in the ICU: How to Approach, How to Treat
Paramythiotou, E., Frantzeskaki, F. G., Flevari, A., Armaganidis, A., & Dimοpoulos, G. (2014) · Molecules · doi:10.3390/molecules19011085 · Cited by 177 · see citing works
New pathogens, new tricks: emerging, drug‐resistant fungal pathogens and future prospects for antifungal therapeutics
Geddes‐McAlister, J., & Shapiro, R. S. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13739 · Cited by 159 · see citing works
Multicenter Evaluation of a New Disk Agar Diffusion Method for Susceptibility Testing of Filamentous Fungi with Voriconazole, Posaconazole, Itraconazole, Amphotericin B, and Caspofungin
Espinel-Ingroff, A., Arthington-Skaggs, B., Iqbal, N., Ellis, D., Pfaller, M. A., Messer, S., Rinaldi, M., Fothergill, A., Gibbs, D. L., & Wang, A. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00134-07 · Cited by 182 · see citing works
Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Order Mucorales
Vitale, R. G., de Hoog, S., Schwarz, P., Dannaoui, É., Deng, S., Machouart, M., Voigt, K., van de Sande, W. W. J., Dolatabadi, S., Meis, J. F. G. M., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.06133-11 · Cited by 155 · see citing works
Why is mucormycosis more difficult to cure than more common mycoses?
Katragkou, A., Walsh, T. J., & Roilides, E. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12466 · Cited by 154 · see citing works
Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring
Dolton, M. J., Ray, J. E., Marriott, D. J. E., & McLachlan, A. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05900-11 · Cited by 148 · see citing works
Mecanismos de resistencia a los antifúngicos: levaduras y hongos filamentosos
Espinel‐Ingroff, A. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70027-5 · Cited by 139 · see citing works
The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals
Nivoix, Y., Levêque, D., Herbrecht, R., Koffel, J.-C., Beretz, L., & Ubeaud-Séquier, G. (2008) · Clinical Pharmacokinetics · doi:10.2165/0003088-200847120-00003 · Cited by 136 · see citing works
New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance
Fera, M. T., Camera, E. L., & Sarro, A. D. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.67 · Cited by 134 · see citing works
Posaconazole: An extended-spectrum triazole antifungal agent
SCHILLER, D., & Fung, H. B. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.015 · Cited by 135 · see citing works
Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole
Walravens, J., Brouwers, J., Spriet, I., Tack, J. F., Annaert, P., & Augustijns, P. (2011) · Clinical Pharmacokinetics · doi:10.2165/11592630-000000000-00000 · Cited by 131 · see citing works
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria
Pfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130 · see citing works
In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of RareCandidaSpecies as Determined by CLSI Broth Microdilution Methods
Diekema, D. J., Messer, S. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Tendolkar, S., & Pfaller, M. A. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00942-09 · Cited by 125 · see citing works
Medical management of allergic fungal rhinosinusitis following endoscopic sinus surgery: an evidence‐based review and recommendations
Gan, E. C., Thamboo, A. V., Rudmik, L. R., Hwang, P. H., Ferguson, B. J., & Javer, A. R. (2014) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21352 · Cited by 122 · see citing works
An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy
Emami, S., Tavangar, P., & Keighobadi, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.044 · Cited by 120 · see citing works
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries
Pagano, L., Cornely, O. A., Busca, A., Caira, M., Cesaro, S., Gasbarrino, C., Girmenia, C., Heinz, W., Herbrecht, R., Lass‐Flörl, C., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.083063 · Cited by 120 · see citing works
In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species
Pfaller, M. A., Messer, S. A., Boyken, L. B., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00535-08 · Cited by 119 · see citing works
Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans
Hens, B., Brouwers, J., Corsetti, M., & Augustijns, P. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24690 · Cited by 116 · see citing works
Safety, Tolerance, and Efficacy of Posaconazole Therapy in Patients with Nonmeningeal Disseminated or Chronic Pulmonary Coccidioidomycosis
Catanzaro, A., Cloud, G. A., Stevens, D. A., Levine, B. E., Williams, P., Johnson, R. H., Rendón, A., Mirels, L. F., Lutz, J. E., Holloway, M., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/519937 · Cited by 116 · see citing works
Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations
Stott, K. E., & Hope, W. W. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx029 · Cited by 115 · see citing works
Effect of pH on In Vitro Susceptibility of Candida glabrata and Candida albicans to 11 Antifungal Agents and Implications for Clinical Use
Danby, C. S., Boikov, D. A., Rautemaa‐Richardson, R., & Sobel, J. D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05025-11 · Cited by 114 · see citing works
Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex
Al‐Hatmi, A. M. S., van Diepeningen, A. D., Curfs-Breuker, I., de Hoog, S., & Meis, J. F. G. M. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku505 · Cited by 107 · see citing works
Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole
Espinel-Ingroff, A., Pfaller, M. A., Bustamante, B., Canton, E., Fothergill, A., Fuller, J., Gonzalez, G. M., Lass-Flörl, C., Lockhart, S. R., Martin-Mazuelos, E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02615-13 · Cited by 105 · see citing works
Therapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults
Lebeaux, D., Lanternier, F., Elie, C., Suárez, F., Buzyn, A., Viard, J., Bougnoux, M., Lecuit, M., Jullien, V., & Lortholary, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00939-09 · Cited by 104 · see citing works
Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections
Lakhani, P. M., Patil, A., & Majumdar, S. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0089 · Cited by 102 · see citing works
Emerging moulds: epidemiological trends and antifungal resistance
Miceli, M. H., & Lee, S. A. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02032.x · Cited by 100 · see citing works
Scedosporium apiospermum (Pseudoallescheria boydii) Infection in Lung Transplant Recipients
Sahi, H., Avery, R. K., Minai, O. A., Hall, G. S., Mehta, A. C., Raina, P., & Budev, M. M. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.01.011 · Cited by 100 · see citing works
BioluminescentAspergillus fumigatus, a New Tool for Drug Efficiency Testing and In Vivo Monitoring of Invasive Aspergillosis
Brock, M., Jouvion, G., Droin-Bergère, S., Dussurget, O., Nicola, M., & Ibrahim-Granet, O. (2008) · Applied and Environmental Microbiology · doi:10.1128/aem.01288-08 · Cited by 99 · see citing works
Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies
Espinel-Ingroff, A. V., Johnson, E. M., Hockey, H. P., & Troke, P. F. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm518 · Cited by 99 · see citing works
Aspergillus to Zygomycetes: Causes, Risk Factors, Prevention, and Treatment of Invasive Fungal Infections
Cornely, O. A. (2008) · Infection · doi:10.1007/s15010-008-7357-z · Cited by 97 · see citing works
New heterocyclic compounds from 1,2,4-triazole and 1,3,4-thiadiazole class bearing diphenylsulfone moieties. Synthesis, characterization and antimicrobial activity evaluation
Bărbuceanu, Ș., Șaramet, G., Almajan, G. L., Draghici, C. C., Bărbuceanu, F., & Bancescu, G. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.031 · Cited by 96 · see citing works
Universal In Vitro Antifungal Resistance of Genetic Clades of the Fusarium solani Species Complex
Azor, M., Gené, J., Cano, J., & Guarro, J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01618-06 · Cited by 95 · see citing works
Antifungal Therapy: New and Evolving Therapies
Nivoix, Y., Ledoux, M., & Herbrecht, R. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-3400291 · Cited by 92 · see citing works
Recent advances in the understanding and management of mucormycosis
Pilmis, B., Alanio, A., Lortholary, O., & Lanternier, F. (2018) · F1000Research · doi:10.12688/f1000research.15081.1 · Cited by 91 · see citing works
Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease
Maertens, J. A., Cornely, O. A., Ullmann, A. J., Heinz, W., Krishna, G., Patino, H., Caceres, M., Kartsonis, N. A., Waskin, H. A., & Robertson, M. N. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02686-13 · Cited by 90 · see citing works
Two Clinical Isolates of Candida glabrata Exhibiting Reduced Sensitivity to Amphotericin B Both Harbor Mutations in <i>ERG2</i>
Hull, C. M., Bader, O., Parker, J. E., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01145-12 · Cited by 90 · see citing works
Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Krishna, G., Abutarif, M. A., Xuan, F., Martinho, M., Angulo, D. A., & Cornely, O. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.10.1223 · Cited by 89 · see citing works
In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates
Seifert, H., Aurbach, U., Stefanik, D., & Cornely, O. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01217-06 · Cited by 85 · see citing works
Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole at Steady State in Healthy Subjects
Conte, J. E., Golden, J. A., Krishna, G., McIver, M., Little, E., & Zurlinden, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00663-08 · Cited by 84 · see citing works
Is Azole Resistance in Aspergillus fumigatus a Problem in Spain?
Escribano, P., Peláez, T., Muñóz, P., Bouza, E., & Guinea, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02487-12 · Cited by 85 · see citing works
Synthesis and anti-inflammatory activity evaluation of novel triazolyl-isatin hybrids
Sharma, P. K., Balwani, S., Mathur, D., Malhotra, S., Singh, B. K., Prasad, A. K., Len, C., der Eycken, E. V. V., Ghosh, B., Richards, N. G. J., et al. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2016.1151015 · Cited by 83 · see citing works
Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14α-demethylase
Caramalho, R., Tyndall, J. D. A., Monk, B. C., Larentis, T., Lass‐Flörl, C., & Lackner, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-16123-9 · Cited by 83 · see citing works
Clinical pharmacodynamics and pharmacokinetics of the antifungal extended‐spectrum triazole posaconazole: an overview
Lipp, H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03680.x · Cited by 82 · see citing works
Fungal infections after lung transplantation
Solé, A., & Salavert, M. (2008) · Transplantation Reviews · doi:10.1016/j.trre.2007.12.007 · Cited by 82 · see citing works
Impact of Antifungal Prophylaxis on Colonization and Azole Susceptibility of Candida Species
Mann, P. A., McNicholas, P. M., Chau, A. S., Patel, R. J., Mendrick, C. A., Ullmann, A. J., Cornely, O. A., Patino, H., & Black, T. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01031-09 · Cited by 81 · see citing works
Antifungal Susceptibility Testing of Fusarium: A Practical Approach
Al‐Hatmi, A. M. S., Curfs-Breuker, I., de Hoog, S., Meis, J. F. G. M., & Verweij, P. E. (2017) · Journal of Fungi · doi:10.3390/jof3020019 · Cited by 84 · see citing works
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease
Cornely, O. A., Robertson, M. N., Haider, S., Grigg, A., Geddes, M. N., Aoun, M., Heinz, W., RAAD, I. I., Schanz, U., Meyer, R. G., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx263 · Cited by 80 · see citing works
Alternaria Keratitis: Clinical Presentation and Resolution With Topical Fluconazole or Intrastromal Voriconazole and Topical Caspofungin
Tu, E. Y. (2008) · Cornea · doi:10.1097/ico.0b013e31818225f8 · Cited by 77 · see citing works
Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications
Autmizguine, J., Guptill, J. T., Cohen‐Wolkowiez, M., Benjamin, D. K., & Capparelli, E. V. (2014) · Drugs · doi:10.1007/s40265-014-0227-3 · Cited by 75 · see citing works
Posaconazole as Salvage Therapy in Patients With Invasive Fungal Infections After Solid Organ Transplant
Alexander, B. D., Perfect, J. R., Daly, J. S., Restrepo, Á., Tobón, Á. M., Patino, H., Hardalo, C. J., & Graybill, J. R. (2008) · Transplantation · doi:10.1097/tp.0b013e3181837585 · Cited by 74 · see citing works
Efficacy, Safety, and Breakthrough Infections Associated with Standard Long-Term Posaconazole Antifungal Prophylaxis in Allogeneic Stem Cell Transplantation Recipients
Winston, D. J., Bartoni, K., Territo, M. C., & Schiller, G. J. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.04.017 · Cited by 73 · see citing works
Fusarium Infection in Lung Transplant Patients
Carneiro, H. A., Coleman, J. J., Restrepo, A., & Mylonakis, E. E. (2010) · Medicine · doi:10.1097/md.0b013e318207612d · Cited by 73 · see citing works
Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-Hour CLSI BMD Method for Testing Susceptibility of Candida Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff Values
Pfaller, M. A., Espinel‐Ingroff, A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02441-10 · Cited by 73 · see citing works
Synthesis and Biological Activity of Substituted Urea and Thiourea Derivatives Containing 1,2,4-Triazole Moieties
Koçyiğit‐Kaymakçıoğlu, B., Celen, A., Tabanca, N., Alı, A., Khan, S. I., Khan, I. A., & Wedge, D. E. (2013) · Molecules · doi:10.3390/molecules18033562 · Cited by 73 · see citing works
Novel antifungal agents: a patent review (2011 – present)
Castelli, M. V., Butassi, E., Monteiro, M. C., Svetaz, L. A., Vicente, F., & Zacchino, S. A. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.876993 · Cited by 72 · see citing works
Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study.
Badiee, P., & Alborzi, A. (2011) · Europe PMC (PubMed Central) · Cited by 72 · see citing works
Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies
Maertens, J. A. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00805.x · Cited by 71 · see citing works
Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: A phase I, randomized, open-label, crossover study in healthy volunteers
Krishna, G., Moton, A., Ma, L., Savant, I. A., Martinho, M., Seiberling, M., & McLeod, J. F. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.022 · Cited by 68 · see citing works
Comparativein vitroactivities of posaconazole, voriconazole, itraconazole, and amphotericin B againstAspergillusandRhizopus, and synergy testing forRhizopus
Arıkan, S., Sancak, B., Alp, Ş., Hasçelik, G., & McNicholas, P. M. (2008) · Medical Mycology · doi:10.1080/13693780801975576 · Cited by 68 · see citing works
A Five-Year Survey of Dematiaceous Fungi in a Tropical Hospital Reveals Potential Opportunistic Species
Yew, S. M., Chan, C. L., Lee, K. W., Na, S. L., Tan, R., Hoh, C.-C., Yee, W.-Y., Ngeow, Y. F., & Ng, K. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104352 · Cited by 67 · see citing works
In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba
Zaragozí, M. T. I., Martínez, G., Curfs-Breuker, I., Fernández, C. M., Boekhout, T., & Meis, J. F. G. M. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01384-07 · Cited by 67 · see citing works
In Vitro Activities of Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole against 45 Clinical Isolates of Zygomycetes: Comparison of CLSI M38-A, Sensititre YeastOne, and the Etest
Torres-Narbona, M., Guinea, J., Martínez-Alarcón, J., Peláez, T., & Bouza, E. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01539-06 · Cited by 66 · see citing works
How Does Antifungal Pharmacology Differ for Mucormycosis Versus Aspergillosis?
Lewis, R. E., Lortholary, O., Spellberg, B. J., Roilides, E., Kontoyiannis, D. P., & Walsh, T. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir884 · Cited by 66 · see citing works
Approaches to the Management of Invasive Fungal Infections in Hematologic Malignancy and Hematopoietic Cell Transplantation
Michallet, M., & Ito, J. I. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1178 · Cited by 64 · see citing works
Chromoblastomycosis
Torres‐Guerrero, E., Isa‐Isa, R., Isa, M., & Arenas, R. (2012) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2011.09.011 · Cited by 65 · see citing works
Fungal infections after lung transplantation
Solé, A., & Salavert, M. (2009) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328326f410 · Cited by 64 · see citing works
Chronic mucocutaneous candidiasis, from bench to bedside
Eyerich, K., Eyerich, S., Hiller, J., Behrendt, H., & Traidl‐Hoffmann, C. (2010) · European Journal of Dermatology · doi:10.1684/ejd.2010.0910 · Cited by 64 · see citing works
In VitroAntifungal Activity of Isavuconazole against 345 Mucorales Isolates Collected at Study Centers in Eight Countries
Verweij, P. E., González, G. M., Wiederhold, N. P., Lass‐Flörl, C., Warn, P. A., Heep, M., Ghannoum, M. A., & Guinea, J. (2009) · Journal of Chemotherapy · doi:10.1179/joc.2009.21.3.272 · Cited by 63 · see citing works
Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine?
Hof, H. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.01.001 · Cited by 60 · see citing works
Posaconazole inhibits dengue virus replication by targeting oxysterol-binding protein
Meutiawati, F., Bezemer, B., Strating, J. R. P. M., Overheul, G. J., Žusinaite, E., van Kuppeveld, F. J. M., van Cleef, K. W. R., & van Rij, R. P. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.06.017 · Cited by 59 · see citing works
Review of the New Delayed‐Release Oral Tablet and Intravenous Dosage Forms of Posaconazole
Guarascio, A. J., & Slain, D. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1533 · Cited by 57 · see citing works
Genetic Analysis Using an Isogenic Mating Pair of Aspergillus fumigatus Identifies Azole Resistance Genes and Lack of MAT Locus’s Role in Virulence
Losada, L. C., Sugui, J. A., Eckhaus, M., Chang, Y. C., Mounaud, S. H., Abigail, F., Joardar, V., Pakala, S., Pakala, S. M., Venepally, P., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004834 · Cited by 58 · see citing works
Posaconazole/hydroxypropyl-β-cyclodextrin host–guest system: Improving dissolution while maintaining antifungal activity
Tang, P., Ma, X., Wu, D., Li, S., Xu, K., Tang, B., & Li, H. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.01.042 · Cited by 58 · see citing works
Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents
Zhao, S., Zhang, X., Peng, W. J., Su, X., Zhao, L., Wu, M., Hao, C., Liu, C., Zhao, D., & Cheng, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.043 · Cited by 58 · see citing works
Traditional and Emerging Antifungal Therapies
Arnold, T. M., Dotson, E. K., Sarosi, G. A., & Hage, C. A. (2010) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200906-048al · Cited by 57 · see citing works
Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men
Krishna, G., Sansone‐Parsons, A., & Kantesaria, B. S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x187937 · Cited by 57 · see citing works
Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi‐centre study
Schmalreck, A., Willinger, B., Haase, G., Blum, G., Lass‐Flörl, C., Fegeler, W., Becker, K., & for the Antifungal Susceptibility Testing (AFST) Study Group (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02165.x · Cited by 57 · see citing works
The clinical spectrum of Exophiala jeanselmei, with a case report and in vitro antifungal susceptibility of the species
Badali, H., Najafzadeh, M. J., Esbroeck, M. V., den Enden, E. V., Tarazooie, B., Meis, J. F. G. M., & de Hoog, S. (2009) · Medical Mycology · doi:10.1080/13693780903148353 · Cited by 56 · see citing works

In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2862-2864.2001 · Cited by 143 · see citing works
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother
Cuenca-estrella, M., Gomez-lopez, A., Mellado, E., Buitrago, M. J., Monzón, A., & Rodriguez-tudela, J. L. (2006)
Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi
Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., & Rodriguez-Tudela, J. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.917-921.2006 · Cited by 298 · see citing works
In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes
Sun, Q. N., Fothergill, A. W., McCarthy, D. I., Rinaldi, M. G., & Graybill, J. R. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1581-1582.2002 · Cited by 365 · see citing works
In vitro antifungal activity of posaconazole against various pathogenic fungi
Uchida, K., Yokota, N., & Yamaguchi, H. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(01)00363-6 · Cited by 68 · see citing works

Authors: Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., & McNicholas, P. M.
Affiliations: Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
ORCID: Mann, P. A.
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2006-06
Volume: 50
Issue: 6
Pages: 2009-2015
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.00163-06
OpenAlex: W2139126851
Cited by: 491
References: 38
Citations by year: 2026: 8 · 2025: 13 · 2024: 8 · 2023: 8 · 2022: 13 · 2021: 16 · 2020: 17 · 2019: 16 · 2018: 37 · 2017: 20 · 2016: 21 · 2015: 26 · 2014: 33 · 2013: 23 · 2012: 27
FWCI: 28.15
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
Keywords: posaconazole, fluconazole, itraconazole, voriconazole, amphotericin B, antifungal susceptibility, minimum inhibitory concentration, molds, yeast, Candida, Cryptococcus, Aspergillus, Zygomycetes, triazole antifungals, antifungal resistance, in vitro antifungal activity
MeSH terms: Amphotericin B, Antifungal Agents, Aspergillosis, Aspergillus, Candida, Candidiasis, Cryptococcosis, Cryptococcus, Fungi, Humans, Microbial Sensitivity Tests, Mycoses, Pyrimidines, Triazoles, Fluconazole, Itraconazole, Drug Resistance, Fungal, Voriconazole, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks